Search This Blog

Friday, December 9, 2022

Why older Americans have left the workforce

 One of the many challenges facing the Federal Reserve is that the labor force participation rate is still lower than it was before the pandemic. The fewer workers in the jobs market, the more wages will be elevated, and the more that wages are elevated, the tougher it will be to bring down inflation.

And drilling further into the data, the participation rate for those between 25 and 54 years old actually has recovered, but the participation of those 55 years and older is still below pre-pandemic levels.

Dhaval Joshi, chief strategist of BCA Research's Counterpoint, points out that most industrialized countries aren't having this problem, and in fact, the participation of workers 50 and over has actually increased in Germany, France and Japan. So why is that American, and also British, older workers have left the workforce?

Joshi gives two reasons, or as he puts it, a carrot and a stick. First, the carrot -- as everyone remembers, the stock market began to skyrocket soon after the pandemic started, thanks to the unprecedented rescue efforts by both fiscal and monetary authorities. But Americans and Brits had far bigger exposure to this boost than the rest of the world. German and French households had lower exposure to financial assets, while Japanese households saw less of a boost because their bond yields were already at the lower bound.

Now for the stick. The U.S. and the U.K. had the highest rate of hospitalizations from COVID. And COVID of course disproportionately harms the older population.

This issue of older workers out of the jobs market won't be easily rectified, even as financial market gains have dissipated, and COVID has faded to the background, because the workers retired.

There are investment implications. The Fed, and the Bank of England, will have to be hawkish for longer. Joshi recommended going overweight French 10-year government bonds over their U.S. equivalent. He says the Fed will have to choke U.S. labor demand by hitting sales and profits, so stock markets will remain under pressure through the first half of 2023, "after which there will be a great buying opportunity," he says.

https://www.morningstar.com/news/marketwatch/20221209323/heres-what-resolves-the-big-mystery-on-why-older-americans-have-left-the-workforce

ImmunoGen Announces Clinical Collaboration with Gilead in Leukemia

 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine (pivekimab) in combination with magrolimab, a potential, first-in-class, investigational CD47 inhibitor, in patients with relapsed or refractory (R/R) CD123-positive acute myeloid leukemia (AML).

Expected to initiate in 2023, the collaboration will be a new cohort in ImmunoGen's 802 study and will evaluate pivekimab in combination with magrolimab in up to 42 patients with R/R CD123-positive AML. The primary endpoint for this cohort is complete response (CR) rate. ImmunoGen's 802 study is an open-label, multicenter, Phase 1b/2 trial to determine the safety and tolerability of pivekimab and assess the anti-leukemia activity of the agent when administered in combination with Vidaza® (azacitidine) and/or Venclexta® (venetoclax) in patients with relapsed and frontline CD123-positive AML.

https://finance.yahoo.com/news/immunogen-announces-clinical-collaboration-gilead-113000245.html

Exelixis: Lung cancer therapy fails in Phase 3

 Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) without actionable mutations who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy.

The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent, and no new safety signals were identified. Detailed findings from CONTACT-01 will be submitted for presentation at a future medical meeting.\

https://finance.yahoo.com/news/exelixis-provides-phase-3-contact-210500842.html

'It's dead out here': China's slow exit from zero-COVID

 Judging by Friday's quiet streets in China's capital Beijing and the reluctance of some businesses to drop COVID curbs, enduring anxieties about the coronavirus are likely to hamper a speedy return to health for the world's second-largest economy.

Although the government on Wednesday loosened key parts of its strict "zero-COVID" policy that has kept the pandemic largely at bay for the past three years, many people appear wary of being too quick to shake off the shackles.

In the central city of Wuhan, where the new coronavirus erupted in late 2019, there were more signs of life with some areas busy with commuters on Friday. But residents say a return to normal is a long way off.

"They've relaxed the measures but still there's nobody about," said a taxi driver surnamed Wang, who didn't want to give his full name.

"You see these roads, these streets ... they ought to be, busy, full of people. But there's no one. It's dead out here."

Yet China has been anything but placid during the past few weeks, with protests against COVID curbs in many cities that marked the biggest show of public discontent since President Xi Jinping came to power a decade ago.

Some of those protesters, tracked down by China's security apparatus, now face an anxious wait about their fate.

CHANGING MIND-SET

Little more than a month after the National Health Commission stressed commitment to its strict virus containment policy, saying it was "putting people and lives first", authorities have changed tack and are now telling people they have less to fear.

Zhong Nanshan, a prominent Chinese epidemiologist, said that 99% of people now infected with the virus would recover in 7 to 10 days, in comments reported by the People's Daily, controlled by the ruling Communist Party.

But there are signs the reassuring new message has still to convince many of the country's 1.4 billion people.


Arizona's Sinema switches political affiliation to independent

 

Arizona U.S. Senator Kyrsten Sinema is switching her political party affiliation from Democrat to independent, she told Politico in an interview on Friday, just days after Democrats won a U.S. Senate race in Georgia to secure 51 seats in the chamber.

Sinema in the interview said she would not caucus with the Republican Party, Politico said.

https://www.marketscreener.com/news/latest/Arizona-s-Sinema-switches-political-affiliation-to-independent-Politico--42513718/

Autolus announces primary endpoint met in leukemia trial

 Autolus Therapeutic Plc. (Nasdaq: AUTL), a clinical-stage biopharma and a portfolio company of Syncona Ltd., has announced that the pivotal phase 2 FELIX clinical trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukaemia (ALL) patients has met its primary endpoint of overall remission rate (ORR) at interim analysis.

The achievement of the primary endpoint (PDF) milestone triggers a $35 million payment from Blackstone Life Sciences, Autolus also announcing an additional $35 million from Blackstone as a result of the completion of planned activities supporting the obe-cel manufacturing process.

Autolus develops next-generation, programmed T cell therapies for the treatment of cancer. Its pipeline includes product candidates in development for the treatment of haematological malignancies and solid tumours.

Obe-cel (AUTO1), a CD19 CAR T cell investigational therapy, demonstrated an ORR – defined as the proportion of patients achieving Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (Cri) – of 70% in interim analysis of 50 patients. Obe-cel showed comparable expansion and initial persistence (median follow-up 6.4 months) to the data observed in the prior ALLCAR19 study.

There was also encouraging safety data observed within a wider group of 92 patients: 3% of patients experienced Grade 3 or higher cytokine release syndrome (CRS) and 8% experienced Grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS).

This means that enrolment is now completed for the initial target or morphological cohort to form the basis of a Biological License Application (BLA) submission by the end of CY2023 to the US Food and Drug Administration (FDA).

CEO and chair of Syncona Investment Management Limited, Martin Murphy, said: “The data is consistent with what was previously presented in the ALLCAR19 academic study, underlining the potential of obe-cel as a drug which can provide meaningful impact for patients suffering from ALL, whilst also showing a very positive safety profile in the last line setting.”

Associate attending physician at the Memorial Sloan Kettering Cancer Center, Dr Jae Park, said: “Obe-cel’s high level of anti-leukaemia activity, combined with a well-manageable tolerability profile, is a significant step forward in this underserved disease setting, which is characterised by the explosive growth of the leukaemia and the poor condition of many patients.”

In collaboration with Autolus’ academic partner, University College London, obe-cel is currently also being evaluated in a phase 1 clinical trial for B-Cell Non-Hodgkin Lymphoma (B-NHL).

Concurrently, Autolus has announced the pricing of its underwritten public offering (PDF) in the US of 75 million American Depositary Shares (ADSs), representing 75 million ordinary shares, at a public offering price of $2 per ADS, for total gross proceeds of approximately $150 million (£122.5 million).

Syncona has agreed to invest circa $28 million (£22.9 million) in the offering, not long after announcing that its newly established portfolio company was to acquire all outstanding shares of Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company focused on the development and commercialisation of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases. The tender offer for that acquisition was approximately $23.5 million in cash ($0.34 per share).

https://pharmaphorum.com/news/autolus-announces-primary-endpoint-met-in-felix-trial-prices-public-offering/

Walgreens cuts stake in AmerisourceBergen through $1 billion share sale

 Walgreens Boots Alliance has sold some AmerisourceBergen Corp's shares for proceeds of $1 billion, the U.S. drugstore chain said on Thursday, further cutting its ownership in the drug distributor, by 3% to about 17%.

Walgreens, which will remain AmerisourceBergen' largest shareholder, said it would use the proceeds to pay down debt and to fund strategic priorities, including Walgreens-backed VillageMD's $9 billion acquisition of urgent care provider Summit Health.

Walgreens had earlier committed $3.5 billion, through an even mix of debt and equity, to support the deal, which was struck on Nov. 7.

A day later, Walgreens said it cut its stake in AmerisourceBergen (ABC) to about 20% from about 26% though a public offering of 10 million ABC shares.

The latest share sale includes $200 million that ABC will buy back from Walgreens under its share repurchase program, ABC said in a separate press release, adding these shares would be held in treasury.

The share sale has no impact on the long-term partnership between the two companies, Walgreens said.

https://finance.yahoo.com/news/walgreen-sells-shares-amerisourcebergen-1-020355369.html